This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (11)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Thomas J. Vecchio, MD; Christine V. Linden, MS; Martin J. O'Connell, PhD; Jill Heilman, MPH

Arch Intern Med. 1982;142(4):721-723.

Abstract
• A multiclinic study was performed comparing colestipol hydrochloride, clofibrate, and placebo in 245 patients with type IIa hyperlipoproteinemia. Eighty-five subjects took colestipol hydrochloride in progressive doses of 15, 20, and 30 g/day; 87 took 2.0 g/day of clofibrate; and 73 took placebo over the six months of study. Colestipol lowered total cholesterol level 20.9% in comparison with clofibrate (14.6%) (statistically significant at months 3, 5, and 6), and lowered low-density lipoprotein cholesterol level 28.8% in comparison with clofibrate (14.8%) (significant at months 2, 4, and 6, all times measured). High-density lipoprotein cholesterol level remained unchanged in all groups. Clofibrate lowered total triglyceride levels 22.5%, compared with an increase of 12.5% in the colestipol group and 11.1% in the placebo group (significant at all time intervals). Colestipol was more effective than clofibrate in lowering the cholesterol fractions associated with increased cardiovascular risk.

(Arch Intern Med 1982;142:721-723)

Author Affiliations
From the Upjohn Co, Kalamazoo, Mich.

Footnotes
Accepted for publication Dec 15, 1981.

Reprint requests to the Upjohn Co, Kalamazoo, MI 49001 (Dr Vecchio).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials
Birjmohun et al.
J Am Coll Cardiol 2005;45:185-197.
ABSTRACT | FULL TEXT  

Dietary Administration of Colesevelam Hydrochloride Does Not Affect Fertility or Reproductive Performance in Rats
Marquis et al.
International Journal of Toxicology 2004;23:357-367.
ABSTRACT | FULL TEXT  

Colesevelam Hydrochloride (Cholestagel): A New, Potent Bile Acid Sequestrant Associated With a Low Incidence of Gastrointestinal Side Effects
Davidson et al.
Arch Intern Med 1999;159:1893-1900.
ABSTRACT | FULL TEXT  

Reducing High Blood Cholesterol Level With Drugs: Cost-effectiveness of Pharmacologic Management
Schulman et al.
JAMA 1990;264:3025-3033.
ABSTRACT